SCHEMBL20180751

SCHEMBL20180751

C[C@@H]1CN(c2ccc(N)c(F)c2)C[C@H](C)N1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.38
HTT P42858 3/20 0.38
TGFBR1 P36897 2/20 0.38
ACVR1 Q04771 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 2/20 0.38
RECQL P46063 1/20 0.38
PTK2B Q14289 1/20 0.38
KCNH2 Q12809 1/20 0.38
ALDH1A1 P00352 2/20 0.37
C1S P09871 2/20 0.35
CHRM4 P08173 2/20 0.34
F10 P00742 1/20 0.34
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
S100B P04271 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30565932 0.85 MAPT (0.41) GAAHTTTGFBR1ACVR1MAPT
SCHEMBL23072821 0.85 MAPT (0.41) GAAHTTTGFBR1ACVR1MAPT
SCHEMBL20292786 0.85 MAPT (0.41) GAAHTTTGFBR1ACVR1MAPT
SCHEMBL20180514 0.82 GAA (0.50) GAAHTTTGFBR1ACVR1MAPT
SCHEMBL20180729 0.82 DGAT1 (0.41) HTTTGFBR1ACVR1MAPTKCNH2
SCHEMBL30279171 0.81 MAPT (0.44) GAAHTTMAPTKDM4EALDH1A1
SCHEMBL13716407 0.81 MAPT (0.44) GAAHTTMAPTKDM4EALDH1A1
SCHEMBL20180513 0.81 MAPT (0.39) GAAHTTTGFBR1ACVR1MAPT
SCHEMBL20180512 0.80 WDR5 (0.38) GAAHTTMAPTMAPK1KDM4E
SCHEMBL27039044 0.78 TGFBR1 (0.36) GAAHTTTGFBR1ACVR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 EP disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 CN disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 US disclosed
EP-3543242-A1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND Impact Therapeutics, Inc (CN) 2019-09-25 EP disclosed
WO-2018090939-A1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND 上海瑛派药业有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 GAA 1036/4885HTT 4468/4885TGFBR1 2478/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 GAA 1036/4885HTT 4468/4885TGFBR1 2478/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 GAA 1036/4885HTT 4468/4885TGFBR1 2478/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 GAA 1036/4885HTT 4468/4885TGFBR1 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.